

Lisa A Carey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8324475/publications.pdf>

Version: 2024-02-01

251
papers

31,076
citations

6613

79
h-index

4774

169
g-index

258
all docs

258
docs citations

258
times ranked

30287
citing authors

#	ARTICLE	IF	CITATIONS
1	Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA - Journal of the American Medical Association, 2006, 295, 2492.	7.4	3,135
2	The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clinical Cancer Research, 2007, 13, 2329-2334.	7.0	1,786
3	The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 2006, 7, 96.	2.8	1,169
4	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	27.0	789
5	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 2015, 33, 13-21.	1.6	782
6	Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment, 2008, 109, 123-139.	2.5	747
7	Triple-negative breast cancer: disease entity or title of convenience?. Nature Reviews Clinical Oncology, 2010, 7, 683-692.	27.6	708
8	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal of Clinical Oncology, 2020, 38, 1346-1366.	1.6	673
9	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	27.0	601
10	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine, 2015, 372, 134-141.	27.0	598
11	Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. Clinical Cancer Research, 2013, 19, 5505-5512.	7.0	592
12	Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer. Clinical Breast Cancer, 2009, 9, S73-S81.	2.4	546
13	Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. Oncologist, 2013, 18, 123-133.	3.7	454
14	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2012, 30, 2615-2623.	1.6	413
15	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1508-1516.	1.5	401
16	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 1485-1505.	1.6	395
17	Triple-Negative Breast Cancer: Risk Factors to Potential Targets. Clinical Cancer Research, 2008, 14, 8010-8018.	7.0	380
18	Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology, 2012, 30, 3242-3249.	1.6	379

#	ARTICLE	IF	CITATIONS
19	Asparagine bioavailability governs metastasis in a model of breast cancer. <i>Nature</i> , 2018, 554, 378-381.	27.8	362
20	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	1.2	354
21	Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. <i>Clinical Cancer Research</i> , 2010, 16, 6100-6110.	7.0	351
22	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1902-1909.	1.6	351
23	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 542-549.	1.6	336
24	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
25	Molecular Portraits and 70-Gene Prognosis Signature Are Preserved throughout the Metastatic Process of Breast Cancer. <i>Cancer Research</i> , 2005, 65, 9155-9158.	0.9	302
26	Estrogen-Regulated Genes Predict Survival in Hormone Receptor-Positive Breast Cancers. <i>Journal of Clinical Oncology</i> , 2006, 24, 1656-1664.	1.6	300
27	CYP2D6 and tamoxifen: DNA matters in breast cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 576-586.	28.4	287
28	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1049-1062.	2.5	286
29	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011, 43, 1210-1214.	21.4	279
30	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	1.6	276
31	What is triple-negative breast cancer?. <i>European Journal of Cancer</i> , 2008, 44, 2799-2805.	2.8	270
32	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37-298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	13.7	260
33	Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. <i>Cell Reports</i> , 2015, 11, 390-404.	6.4	254
34	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1069.	1.6	254
35	Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 774.	7.4	252
36	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	7.1	242

#	ARTICLE	IF	CITATIONS
37	EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics, 2007, 8, 258.	2.8	234
38	Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer. Clinical Cancer Research, 2014, 20, 3818-3829.	7.0	230
39	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1868-1875.	1.6	229
40	Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer. Journal of the National Cancer Institute, 2014, 106, dju057.	6.3	218
41	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 3307-3329.	1.6	210
42	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Archives of Pathology and Laboratory Medicine, 2020, 144, 545-563.	2.5	205
43	Breast Carcinomas Arising at a Young Age: Unique Biology or a Surrogate for Aggressive Intrinsic Subtypes?. Journal of Clinical Oncology, 2011, 29, e18-e20.	1.6	200
44	Disparities in Breast Cancer Treatment and Outcomes: Biological, Social, and Health System Determinants and Opportunities for Research. Oncologist, 2013, 18, 986-993.	3.7	197
45	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 2015, 33, 2361-2369.	1.6	197
46	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Research and Treatment, 2012, 132, 523-535.	2.5	189
47	American Joint Committee on Cancer Tumor-Node-Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome. Journal of the National Cancer Institute, 2005, 97, 1137-1142.	6.3	185
48	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment, 2012, 133, 1057-1065.	2.5	183
49	Understanding and treating triple-negative breast cancer. Oncology, 2008, 22, 1233-9; discussion 1239-40, 1243.	0.5	179
50	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	178
51	Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study. Journal of Clinical Oncology, 2011, 29, 3232-3239.	1.6	173
52	Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. Cancer Investigation, 2008, 26, 1-10.	1.3	170
53	A compact VEGF signature associated with distant metastases and poor outcomes. BMC Medicine, 2009, 7, 9.	5.5	162
54	Poly(ADP-Ribose) Polymerase Inhibition: -Targeted Therapy for Triple-Negative Breast Cancer. Clinical Cancer Research, 2010, 16, 4702-4710.	7.0	149

#	ARTICLE	IF	CITATIONS
55	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. <i>Cancer Research</i> , 2014, 74, 2160-2170.	0.9	149
56	Directed Therapy of Subtypes of Triple-Negative Breast Cancer. <i>Oncologist</i> , 2011, 16, 71-78.	3.7	148
57	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€™864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	10.7	147
58	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	3.7	145
59	Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. <i>BMC Medical Genomics</i> , 2011, 4, 3.	1.5	142
60	Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 3472-3483.	8.2	130
61	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. <i>Cancer Discovery</i> , 2017, 7, 302-321.	9.4	128
62	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1371-1383.	8.2	126
63	The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. <i>Cancer</i> , 2011, 117, 1602-1611.	4.1	125
64	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. <i>Science Signaling</i> , 2014, 7, ra29.	3.6	123
65	Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women. <i>Oncologist</i> , 2014, 19, 1076-1083.	3.7	122
66	Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast Carcinoma. <i>Annals of Surgery</i> , 2002, 236, 295-303.	4.2	119
67	Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. <i>Journal of the National Cancer Institute</i> , 2018, 110, 176-182.	6.3	104
68	Breast Cancer Molecular Subtypes in Patients With Locally Advanced Disease: Impact on Prognosis, Patterns of Recurrence, and Response to Therapy. <i>Seminars in Radiation Oncology</i> , 2009, 19, 204-210.	2.2	103
69	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€™Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	1.6	101
70	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. <i>JAMA Oncology</i> , 2017, 3, 1043.	7.1	98
71	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
72	The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 874-882.	1.5	91

#	ARTICLE	IF	CITATIONS
73	Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Research and Treatment, 2012, 136, 35-43.	2.5	88
74	Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study. Breast Cancer Research, 2016, 18, 79.	5.0	88
75	Î±B-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain. Clinical Cancer Research, 2014, 20, 56-67.	7.0	87
76	Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. PLoS Medicine, 2016, 13, e1002174.	8.4	86
77	Financial Impact of Breast Cancer in Black Versus White Women. Journal of Clinical Oncology, 2018, 36, 1695-1701.	1.6	85
78	Impact of Breast Cancer Molecular Subtypes on Locoregional Recurrence in Patients Treated with Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Annals of Surgical Oncology, 2011, 18, 2851-2857.	1.5	84
79	Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local Control. Clinical Cancer Research, 2007, 13, 3637-3641.	7.0	83
80	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Research and Treatment, 2012, 134, 401-410.	2.5	81
81	The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 737-749.	2.2	80
82	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer, 2016, 2, .	5.2	80
83	Retention and Use of Breast Cancer Recurrence Risk Information from Genomic Tests: The Role of Health Literacy. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 249-255.	2.5	77
84	Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer. PLoS ONE, 2013, 8, e61359.	2.5	77
85	Current Treatment Paradigms for the Management of Patients with Brain Metastases. Neurosurgery, 2005, 57, S4-66-S4-77.	1.1	76
86	Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial. Journal of the American College of Surgeons, 2009, 208, 906-914.	0.5	74
87	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology, 2020, 38, 4184-4193.	1.6	74
88	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clinical Cancer Research, 2018, 24, 5292-5304.	7.0	73
89	Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. Journal of Clinical Oncology, 2008, 26, 806-813.	1.6	68
90	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 29.	7.1	68

#	ARTICLE	IF	CITATIONS
91	Size of Residual Lymph Node Metastasis After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Is Prognostic. <i>Annals of Surgical Oncology</i> , 2006, 13, 685-691.	1.5	67
92	Axillary lymph node count is lower after neoadjuvant chemotherapy. <i>American Journal of Surgery</i> , 2006, 191, 827-829.	1.8	66
93	Chemotherapy-related amenorrhea after adjuvant paclitaxel+trastuzumab (APT trial). <i>Breast Cancer Research and Treatment</i> , 2015, 151, 589-596.	2.5	65
94	Endocrine Therapy Nonadherence and Discontinuation in Black and White Women. <i>Journal of the National Cancer Institute</i> , 2019, 111, 498-508.	6.3	65
95	Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. <i>Annals of Surgery</i> , 2002, 236, 295-302; discussion 302-3.	4.2	65
96	Improving communication of breast cancer recurrence risk. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 553-561.	2.5	64
97	Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2003-2009.	1.6	64
98	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2016, 160, 297-304.	2.5	63
99	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1323-1334.	1.6	62
100	TBCRC 008: Early Change in ¹⁸ F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.	5.0	61
101	Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. <i>Cancer</i> , 2019, 125, 2945-2954.	4.1	60
102	Dysregulation of the epigenome in triple-negative breast cancers: Basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. <i>Experimental and Molecular Pathology</i> , 2013, 95, 276-287.	2.1	59
103	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	2.5	59
104	Guidelines for the Initial Management of Metastatic Brain Tumors: Role of Surgery, Radiosurgery, and Radiation Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 505-514.	4.9	58
105	Altered-Function p53 Missense Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation. <i>Molecular Cancer Research</i> , 2010, 8, 701-716.	3.4	57
106	Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 500-500.	1.6	57
107	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2338-2348.	1.6	56
108	Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. <i>Oncologist</i> , 2019, 24, 762-771.	3.7	56

#	ARTICLE	IF	CITATIONS
109	Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment, 2017, 165, 181-191.	2.5	54
110	Telomerase Activity and Prognosis in Primary Breast Cancers. Journal of Clinical Oncology, 1999, 17, 3075-3081.	1.6	52
111	PARP and Cancer “If It’s Broke, Don’t Fix It. New England Journal of Medicine, 2011, 364, 277-279.	27.0	52
112	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncology, The, 2020, 21, 1455-1464.	10.7	52
113	Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Research and Treatment, 2004, 88, 273-280.	2.5	50
114	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. Journal of Clinical Investigation, 2020, 130, 4871-4887.	8.2	49
115	Women’s experiences with genomic testing for breast cancer recurrence risk. Cancer, 2010, 116, 1992-2000.	4.1	48
116	I-SPY 2 “Toward More Rapid Progress in Breast Cancer Treatment. New England Journal of Medicine, 2016, 375, 83-84.	27.0	47
117	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Research and Treatment, 2016, 159, 109-118.	2.5	47
118	Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. Journal of Clinical Oncology, 2017, 35, 3298-3305.	1.6	47
119	Gene expression profiling in breast cancer. Current Opinion in Oncology, 2007, 19, 547-551.	2.4	46
120	Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2016, 34, 130-138.	1.6	46
121	Directed Therapy of Subtypes of Triple-Negative Breast Cancer. Oncologist, 2010, 15, 49-56.	3.7	44
122	Women’s Interest in Gene Expression Analysis for Breast Cancer Recurrence Risk. Journal of Clinical Oncology, 2007, 25, 4628-4634.	1.6	42
123	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. Oncologist, 2016, 21, 795-803.	3.7	42
124	Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Research and Treatment, 2014, 145, 245-254.	2.5	41
125	Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Research and Treatment, 2015, 150, 667-674.	2.5	41
126	In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. British Journal of Clinical Pharmacology, 2015, 80, 1122-1130.	2.4	40

#	ARTICLE	IF	CITATIONS
127	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Research and Treatment, 2018, 171, 637-648.	2.5	40
128	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3938-3958.	1.6	40
129	Through a Glass Darkly: Advances in Understanding Breast Cancer Biology, 2000â€“2010. Clinical Breast Cancer, 2010, 10, 188-195.	2.4	39
130	Response and Cardiac Toxicity of Trastuzumab Given in Conjunction with Weekly Paclitaxel After Doxorubicin/Cyclophosphamide. Clinical Breast Cancer, 2006, 7, 237-243.	2.4	38
131	A desensitization protocol for the mAb cetuximab. Journal of Allergy and Clinical Immunology, 2009, 123, 260-262.	2.9	38
132	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Research and Treatment, 2015, 152, 347-356.	2.5	38
133	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 171, 111-120.	2.5	38
134	Treatment of melanoma metastases in the brain. Journal of Surgical Oncology, 1996, 12, 429-435.	1.4	37
135	Blood Vessel Morphologic Changes Depicted with MR Angiography during Treatment of Brain Metastases: A Feasibility Study. Radiology, 2007, 245, 824-830.	7.3	37
136	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 78-86.	3.8	36
137	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2019, 37, 714-722.	1.6	36
138	Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. American Journal of Surgery, 2005, 190, 371-375.	1.8	35
139	Molecular profiling in breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 185-198.	5.7	35
140	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. Clinical Cancer Research, 2015, 21, 1098-1105.	7.0	35
141	Changing Natural History of HER2â€“Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies. Clinical Breast Cancer, 2018, 18, 29-37.	2.4	35
142	Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study. Cancer, 2019, 125, 3985-3992.	4.1	35
143	Targeted Chemotherapy? Platinum in <i>BRCA1</i>-Dysfunctional Breast Cancer. Journal of Clinical Oncology, 2010, 28, 361-363.	1.6	34
144	Breast Cancer Screening in Low- and Middle-Income Countries: A Perspective From Malawi. Journal of Global Oncology, 2016, 2, 4-8.	0.5	34

#	ARTICLE	IF	CITATIONS
145	A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience. <i>Oncologist</i> , 2016, 21, 16-20.	3.7	33
146	Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. <i>Oncology Reports</i> , 2008, 19, 1311-21.	2.6	33
147	Gene-expression analysis and the basal-like breast cancer subtype. <i>Future Oncology</i> , 2007, 3, 55-63.	2.4	32
148	Engaging in Health Behaviors to Lower Risk for Breast Cancer Recurrence. <i>PLoS ONE</i> , 2013, 8, e53607.	2.5	32
149	Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 777-785.	4.2	31
150	Clonal evolution of lymphoblastoid cell lines. <i>Laboratory Investigation</i> , 2006, 86, 1193-1200.	3.7	31
151	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	7.0	31
152	Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 465-470.	2.4	30
153	Localâ€‘regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	2.5	30
154	Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. <i>American Journal of Medicine</i> , 1996, 100, 186-192.	1.5	28
155	Brain metastases. <i>Current Treatment Options in Oncology</i> , 2001, 2, 537-547.	3.0	28
156	Clinical trials in triple negative breast cancer. <i>Breast Disease</i> , 2011, 32, 123-136.	0.8	28
157	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. <i>Clinical Cancer Research</i> , 2020, 26, 2783-2788.	7.0	27
158	ACR Appropriateness Criteria® Conservative surgery and Radiation - Stage I and II Breast Carcinoma. <i>Breast Journal</i> , 2011, 17, 448-455.	1.0	26
159	Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). <i>Breast Cancer Research and Treatment</i> , 2012, 132, 871-879.	2.5	26
160	Congruence of patientâ€‘and clinicianâ€‘reported toxicity in women receiving chemotherapy for early breast cancer. <i>Cancer</i> , 2020, 126, 3084-3093.	4.1	25
161	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancerâ€‘phase 3 ASCENT study subanalysis. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	25
162	Oxygen Radical Scavengers Improve Vascular Patency and Bone-Muscle Cell Survival in an Ischemic Extremity Replant Model. <i>Plastic and Reconstructive Surgery</i> , 1989, 84, 117-123.	1.4	24

#	ARTICLE	IF	CITATIONS
163	Polymorphisms in drug metabolism genes, smoking, and <i>p53</i> mutations in breast cancer. <i>Molecular Carcinogenesis</i> , 2008, 47, 88-99.	2.7	23
164	Defining the expressed breast cancer kinome. <i>Cell Research</i> , 2012, 22, 620-623.	12.0	23
165	Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer. <i>Cancer</i> , 2021, 127, 922-930.	4.1	23
166	A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 99-107.	2.3	22
167	Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 5960-5971.	1.5	22
168	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	1.6	22
169	High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. <i>American Journal of Surgery</i> , 2004, 188, 386-389.	1.8	21
170	A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 289-297.	2.4	21
171	When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 25-29.	2.5	20
172	Defining success in neoadjuvant breast cancer trials. <i>Lancet, The</i> , 2014, 384, 115-116.	13.7	20
173	Weight trajectories in women receiving systemic adjuvant therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 709-720.	2.5	20
174	ACR Appropriateness Criteria® Ductal Carcinoma in Situ. <i>Breast Journal</i> , 2012, 18, 8-15.	1.0	19
175	Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States. <i>Journal of the American College of Surgeons</i> , 2016, 223, 717-728e4.	0.5	19
176	Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women. <i>Journal of the National Cancer Institute</i> , 2020, 112, 728-736.	6.3	19
177	Quantifying the effect of ischemia on epiphyseal growth in an extremity replant model. <i>Journal of Hand Surgery</i> , 1990, 15, 625-630.	1.6	18
178	Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. <i>Breast Cancer Research</i> , 2007, 9, 110.	5.0	18
179	Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?. <i>Clinical Cancer Research</i> , 2017, 23, 2611-2616.	7.0	18
180	Reporting of race and ethnicity in breast cancer research: room for improvement. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 511-517.	2.5	17

#	ARTICLE	IF	CITATIONS
181	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 321-328.	2.5	17
182	ACR Appropriateness Criteria® Locally Advanced Breast Cancer. <i>Breast Journal</i> , 2011, 17, 579-585.	1.0	16
183	HER2® a good addiction. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 196-197.	27.6	16
184	The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1189-1196.	2.3	16
185	A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 99-106.	2.5	16
186	Weight changes in postmenopausal breast cancer survivors over 2Âyears of endocrine therapy: a retrospective chart review. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 375-388.	2.5	16
187	Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 191-200.	2.5	15
188	Toronto Workshop on Late Recurrence in Estrogen Receptor®Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.9	15
189	Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16INK4a</i> . <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa082.	2.9	15
190	Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk. <i>Carcinogenesis</i> , 2006, 27, 2519-2527.	2.8	14
191	Clinical Significance of Circulating Tumor Cells in Hormone Receptor®positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. <i>Clinical Cancer Research</i> , 2020, 26, 4911-4920.	7.0	14
192	Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa072.	2.9	14
193	Phase I Study and Biomarker Analysis of Lapatinib and Concurrent Radiation for Locally Advanced Breast Cancer. <i>Oncologist</i> , 2012, 17, 1496-1503.	3.7	13
194	Understanding how breast cancer patients use risk information from genomic tests. <i>Journal of Behavioral Medicine</i> , 2013, 36, 567-573.	2.1	13
195	Palbociclib ® Taking Breast-Cancer Cells Out of Gear. <i>New England Journal of Medicine</i> , 2015, 373, 273-274.	27.0	13
196	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	6.3	13
197	Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).. <i>Journal of Clinical Oncology</i> , 2014, 32, 506-506.	1.6	13
198	ACR Appropriateness Criteria® Local-regional Recurrence (LR) and Salvage Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 178-182.	1.3	12

#	ARTICLE	IF	CITATIONS
199	De-escalating and escalating systemic therapy in triple negative breast cancer. <i>Breast</i> , 2017, 34, S112-S115.	2.2	12
200	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2189-2192.	1.6	12
201	Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. <i>American Surgeon</i> , 2011, 77, 850-5.	0.8	12
202	Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptorâ€“Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3618-3629.	7.0	12
203	Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). <i>Breast Cancer Research and Treatment</i> , 2017, 166, 793-808.	2.5	11
204	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	2.9	11
205	Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 185-195.	2.5	11
206	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. <i>Npj Breast Cancer</i> , 2021, 7, 51.	5.2	11
207	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4883-4897.	7.0	11
208	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10, e003427.		11
209	Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. <i>PLoS ONE</i> , 2019, 14, e0211488.	2.5	10
210	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. <i>JCO Oncology Practice</i> , 2022, 18, 211-216.	2.9	10
211	Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. <i>NAR Cancer</i> , 2022, 4, .	3.1	10
212	The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 66-88.	0.8	9
213	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptorâ€“Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Antiâ€“HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	7.0	9
214	A plain language summary of the ASCENTâ€“study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2021, 17, 3911-3924.	2.4	9
215	How Low Should We Go? The Search for Balance in Management of Small Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancers. <i>Journal of Clinical Oncology</i> , 2014, 32, 2122-2124.	1.6	8
216	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). <i>Journal of the American College of Surgeons</i> , 2017, 224, 688-694.	0.5	8

#	ARTICLE	IF	CITATIONS
217	Influence of provider factors and race on uptake of breast cancer gene expression profiling. <i>Cancer</i> , 2018, 124, 1743-1751.	4.1	8
218	Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 235-248.	2.5	8
219	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab025.	2.9	8
220	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	2.4	8
221	Old drugs, new tricks for triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2015, 16, 357-359.	10.7	7
222	PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. <i>Cancer Prevention Research</i> , 2018, 11, 327-336.	1.5	7
223	Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. <i>Cancer</i> , 2021, 127, 957-967.	4.1	7
224	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021, 69, 103451.	6.1	7
225	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 571-571.	1.6	6
226	Another Breast Cancer Entity Confirmed: Genomics of Invasive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1838-1839.	1.6	5
227	Neoadjuvant Trials of Human Epidermal Growth Factor Receptor 2 Targeting: How Many Drugs Do We Need?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1909-1911.	1.6	4
228	CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4027-4029.	7.0	4
229	Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715). <i>Oncologist</i> , 2019, 24, e284-e291.	3.7	4
230	Integrating Biology and Access to Care in Addressing Breast Cancer Disparities: 25 Years' Research Experience in the Carolina Breast Cancer Study. <i>Current Breast Cancer Reports</i> , 2020, 12, 149-160.	1.0	4
231	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	4
232	Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 509-509.	1.6	4
233	Neoadjuvant clinical trial designs: Challenges of the genomic era. <i>Breast</i> , 2015, 24, S88-S90.	2.2	3
234	Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2017, 1, pkx004.	2.9	3

#	ARTICLE	IF	CITATIONS
235	Finding the positive in triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 476-478.	13.2	3
236	Novel targets for triple-negative breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 678-80.	0.3	3
237	A chemotherapy privileging process for advanced practice providers at an academic medical center. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 116-123.	0.9	2
238	Clinical Significance of Micrometastatic Disease in the Era of Sentinel Node. <i>Breast Disease</i> , 2001, 12, 57-67.	0.8	1
239	Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 191-194.	2.4	1
240	Emerging therapies for triple-negative breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 47-55.	0.2	1
241	Making Sense of Dual HER2-Targeting in Early Breast Cancer?. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju259-dju259.	6.3	1
242	Research priorities in prediction of response in early breast cancer. <i>Breast</i> , 2019, 48, S31-S33.	2.2	1
243	Benchmarks for Academic Oncology Faculty. <i>JCO Oncology Practice</i> , 2021, 17, e440-e444.	2.9	1
244	Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. <i>Translational Medicine Series</i> , 2007, , 103-120.	0.0	0
245	Treating Triple Negative ABC. <i>Breast</i> , 2017, 36, S30-S31.	2.2	0
246	A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance). <i>Annals of Oncology</i> , 2018, 29, vii50.	1.2	0
247	HITTING A MOVING TARGET: 2019 STANDARDS OF CARE AND TREATMENT OPTIMIZATION FOR HER2+ ABC. <i>Breast</i> , 2019, 48, S29-S30.	2.2	0
248	ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 436-437.	1.5	0
249	Basal-like breast cancers express a hypermethylation defect. <i>FASEB Journal</i> , 2008, 22, 898.23.	0.5	0
250	Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 48-52.	1.5	0
251	A single-arm feasibility trial of memantine to prevent chemotherapy-related cognitive decline in patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12109-12109.	1.6	0